Tacrolismus (FK506) as primary immunosuppressant after lung transplantation

Thoracic and Cardiovascular Surgeon

Volumn 47, Issue 3, 1999, Pages 174-178

  Kur, Felix ^a   Reichenspurner, H ^a   Meiser, B M ^a   Welz, A ^a   Furst H ^a   Muller C ^a   Vogelmeier, C ^a   Schwaiblmaier, M ^a   Briegel, J ^a   Reichart, B ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CyA; Immunosuppression; Lung transplantation; Tacrolimus

Indexed keywords

CYCLOSPORIN A; TACROLIMUS; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ADULT; ARTICLE; BRONCHIOLITIS; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL RATE;

ACTUARIAL ANALYSIS; ADULT; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; SURVIVAL RATE; TACROLIMUS;

EID: 0032587929     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1013136     Document Type: Article

References (20)

1. Starzl TE, Todo S, Fung JJ, et al. FK 506 for liver, kidney, and pancreas trasnplantation. Lancet. 1989;2 : 1000-4.
2. Armitage JM, Kormos RL, Fung JJ, et al. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc. 1992;23 : 3054-7.
3. Bierer BE, Hollander G, Fruman D, et al. Cyclosporin A and FK 506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol. 1993;5 (5) : 763-73.
4. Meiser BM, Ueberfuhr P, Fuchs A, et al. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection following intrathoracic transplantation. J Heart Lung Transpl. 1997;16 (8) : 795-800.
5. Ochiai T, Nakajima K, Nagata M, et al. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc. 1987;19 : 1284-6.
6. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus. A review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs. 1993;46 : 746-94.
7. Morris RE, Wu J, Shorthouse R. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc. 1990; 22 : 1638-41.
8. Murase N, Kim DG, Todo S, et al. Suppression of allograft rejection with FK 506. I. Prolonged cardiac and liver survival in rats following short course therapy. Transplantation. 1990;50 : 1986-9.
9. European Tacrolimus Multicentre Liver Study Group. Randomized trial comparing tacrolimus (FK 506) and cyclosporine in prevention of liver allograft rejection. Lancet. 1994;344 : 423-4.
10. The US Multicenter Tacrolimus Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994;331 : 1110-5.
11. Pham SM, Armitage JM, Kormos RL, et al. Rescue therapy with FK 506 in cardiac transplantation. Circulation. 1993;88 (Suppl.) : 194.
12. Swinnen LJ, Costanzo-Nordin M, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosupression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med. 1990;323 : 1723-8.
13. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg. 1996;111 : 764-72.
14. Jain AB, Fung JJ, Todo S, et al. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc. 1995;27 : 1099-104.
15. US Multicenter Liver Study Group. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US multicenter trial. Transplant Proc. 1995;27 : 1114-6.
16. Armitage JM, Kormos RL, Morita S, et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg. 1992;54 : 205-11.
17. Bäckmann L, Levy MF, Klintmalm G, Tacrolimus Multicenter Study Group. Whole blood and plasma levels of FK 506 after liver transplantation: results from the US multicenter trial. Transplant Proc. 1995;27 : 1124.
18. Burkhalter EL, Strazl TE, van Thiel DH. Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. J Hepatol. 1994; 21 : 572-7.
19. Griffith BP, Bando K, Hardesty RL, et al. A prospective randomized trial of FK 506 versus cyclosporine after human pulmonary transplantation. Transplantation. 1994;57 : 848-51.
20. Reichenspurner H, Girgis RE, Robbins RC, et al. Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg. 1996;62 : 1467-72.